Bryan Blair’s Post

🚀 Attention Talent Acquisition Professionals and Recruiters! 🚀 Are you ready to stay ahead of the curve with artificial intelligence? 🤖 Discover how LiveBench is transforming the way we evaluate and utilize large language models (LLMs) in recruitment. 🧠✨ 🔍 Understanding LiveBench: A Game-Changer in LLM Evaluation 🔍 LiveBench addresses key issues in traditional benchmarks, ensuring more reliable and transparent assessments. It features: Frequently Updated Questions: Models are evaluated on up-to-date information, critical in the fast-paced recruitment world. Objective Scoring: Automatic scoring based on objective ground truth reduces bias. Diverse Question Categories: Comprehensive evaluation across math, coding, reasoning, language comprehension, instruction following, and data analysis. 🌟 Implications for Recruitment and Talent Acquisition 🌟 Enhanced Model Selection: Make informed decisions about LLMs for specific tasks. Example: TechTalent Inc. improved candidate shortlisting accuracy by 20% using a combination of GPT-4 and Claude. Improved Candidate Evaluation: Tailor LLM use for different stages of evaluation. Example: Sarah from a financial services company enhanced screening processes by using Llama 2 for math and data analysis. Continuous Improvement: Stay updated with monthly LiveBench results to adapt recruitment processes. Transparency and Trust: Build trust with candidates and within your organization through transparent AI-assisted processes. 📈 Leveraging LiveBench Insights in Recruitment Workflows 📈 Skill-Specific Model Selection: Choose models excelling in relevant categories. Adaptive Questioning Techniques: Regularly update your question bank. Benchmarking Internal AI Tools: Create role-specific tests for custom AI tools. Enhancing Data Analysis: Incorporate data analysis tasks in assessments. 🔮 Future Outlook: LiveBench and AI in Recruitment 🔮 Expect rapid improvements in LLM capabilities and more sophisticated candidate assessments. By 2025, "LiveBench Certified" LLMs will become standard in AI-assisted recruitment tools. Ready to revolutionize your recruitment process? Dive into the full article for a detailed exploration of LiveBench and its impact on talent acquisition. 🔗 Read the full article below ⬇ 📩 Subscribe to the recruit.ai newsletter for weekly insights on AI in recruitment! #AI #Recruitment #TalentAcquisition #LiveBench #LLM #TechTalent #Hiring #FutureOfWork P.S. What's your biggest challenge with integrating AI into your recruitment process? Share in the comments below! 💬

I deeply wish I had the connections or expertise in the trust and safety field to directly assist Courtney and her son. However, I want to take meaningful action beyond simply reposting. I'm offering a $2,000 reward to anyone in my network who can help Courtney secure a job in this field. The reward will be paid on her first day of employment. If you can help or know someone who can, please reach out.

🔍 Big Pharma's Marketing Spend: AbbVie Takes the Lead In a stunning revelation, pharmaceutical giant AbbVie has set a new record in healthcare provider marketing spend. According to recent data: • AbbVie spent a whopping $145.7 million on marketing to doctors in 2023 • This is the highest amount spent by any pharma company since reporting began in 2017 • For perspective, Pfizer spent $32 million and Merck $22 million in the same period What's driving this massive spend? 1. Post-Humira strategy: With its blockbuster drug Humira facing biosimilar competition, AbbVie is aggressively promoting other products 2. Key focus areas: - Vraylar (antidepressant): $28.1 million - Rinvoq (anti-inflammatory): $18.8 million - Botox: Over $15 million 3. Acquisition impact: The 2020 Allergan acquisition has significantly expanded AbbVie's portfolio and marketing efforts Is this level of spending Effective? What are your thoughts on the influence of pharma marketing on healthcare? #Pharma #Healthcare #Marketing #AbbVie #IndustryTrends

Remote, Hybrid, or In-Office? Evaluating Work Models for #Pharma and #Biotech Talent Acquisition The pandemic has reshaped how we work, prompting pharma and biotech companies to reconsider their work models. ➡️ #Remote Work offers access to a global talent pool, increased diversity, and cost savings, but faces challenges like onboarding, potential isolation, and security concerns. ➡️ #Hybrid Work combines flexibility with structure, balancing innovation and remote benefits, but can be complex to manage and may create inequities. ➡️ #InOffice Work fosters collaboration and innovation, ideal for roles needing hands-on training, yet limits the talent pool and flexibility. 🧪 Key Considerations for Hiring Managers: 🤔 Role nature 🤔 Security requirements 🤔 Collaboration needs 🤔 Candidate preferences 🤔 Company culture Dive deeper into the benefits and challenges of each work model in my latest article on RecruitRx. 🔗 Read the full article below ⬇ P.S. Don't forget to subscribe to the newsletter for more insights! Repost this ♻️ for your network. Thank you!

As we close out Independence Day, I find myself reflecting on the words of Alexis de Tocqueville: "America is great because she is good. If America ceases to be good, America will cease to cease to be great." This profound observation encapsulates the essence of American exceptionalism - not as a birthright, but as an ongoing commitment to our founding principles. In today's complex geopolitical landscape, it's crucial to remember that true patriotism transcends mere nationalism. It demands a nuanced understanding of our nation's history, including both its triumphs and its shortcomings. As leaders in the pharmaceutical and biotech industries, we have a unique opportunity - and responsibility - to embody the best of American innovation and ethical leadership on the global stage. How do you balance patriotism with global citizenship in your professional life? What does "American exceptionalism" mean to you in 2024? Let's engage in a thoughtful dialogue. Your insights could shape the future of our industry and our nation. #AmericanInnovation #EthicalLeadership #PatrioticReflection

🔬 Attention U.S. Biotech and Pharma Professionals: Major Industry Shifts on the Horizon? 🧪 The ongoing scrutiny of Chinese CDMOs, particularly WuXi AppTec, could reshape our industry landscape. Here's what you need to know: 1. The BIOSECURE Act, if passed, could force U.S. drugmakers to cut ties with certain Chinese biotech companies by 2032. This affects over 120 U.S. biopharma drugs currently partnered with these firms. 2. WuXi AppTec's deep integration in U.S. pharma (involved in developing ~25% of drugs used in the U.S.) means any restrictions could have far-reaching effects on drug development pipelines. 3. Indian CDMOs are positioning themselves to potentially fill the gap. With a market estimated at $22 billion and growing, they're ramping up investments in capacity and capabilities. 4. However, challenges remain. Indian CDMOs may face hurdles in small molecule production and need to address quality concerns. 5. We might see a push towards domestic U.S. CDMOs as concerns grow about offshore dependencies. As industry professionals, we need to stay ahead of these potential shifts. How is your organization preparing for possible changes in the CDMO landscape? #Biotech #Pharma #CDMO #DrugDevelopment #RegulatoryChanges

🚀 Biotech Q3 Scorecard: 19 Stock-Moving Events to Watch! 📊 Exciting times ahead in the biotech world! Here are key developments to keep on your radar: Alnylam Pharmaceuticals vutrisiran vs BridgeBio acoramidis for ATTR-CM: ESC presentation in August Novo Nordisk's monlunabant for obesity: Phase 2 results (watch Skye Bioscience Inc. and Corbus, LLC too!) Viridian Therapeutics, Inc.'s VRDN-001 for thyroid eye disease: Phase 3 readout in September Sage Therapeutics' Sage-324 for essential tremor: Mid-stage study results Apellis Pharmaceuticals' Empaveli for kidney diseases: Phase 3 VALIANT study results early Q3 Eli Lilly and Company's bimagrumab for obesity: Phase 2 results mid-year UCB and Biogen's dapirolizumab for lupus: Phase 3 results Neurocrine Biosciences's NBI-1117568 for schizophrenia: Phase 2 results Elevation Oncology's EO-3021 for gastric/pancreatic cancers: Data update Plus: • AstraZeneca's Imfinzi FDA panel (July 25) • Potential approvals for Alzheimer's drugs: Eisai US/Biogen's Leqembi (EU) • Multiple FDA decisions including Gilead Sciences, Regeneron, Syndax Pharmaceuticals, Roche, and Bristol Myers Squibb 🔬 The biotech sector is buzzing with potential breakthroughs. Which company or development are you most excited about? Share your thoughts below! 👇 #Biotech #PharmaTrends #ClinicalTrials #DrugDevelopment

🚀 Breaking: The Future of Pharma is Here! 🧬💊 Exciting times ahead for the pharmaceutical industry in 2024 and beyond! 🌟 Key trends shaping our future: • Anti-obesity medications leading the charge 💪 • Personalized medicine revolutionizing treatment 🔬 • AI and big data transforming healthcare 🤖 • Immuno-oncology breakthroughs saving lives 🩺 But challenges remain: • Drug pricing pressures 💰 • Patent expirations 📅 • Regulatory hurdles 📋 As industry professionals, we must innovate, collaborate, and adapt. Let's embrace these changes and work together to create a healthier world! 🌍 What excites you most about pharma's future? Share your thoughts below! 👇 #Pharma2024 #BiotechInnovation #HealthcareFuture #AI #PersonalizedMedicine